Table 3.
XRCC1 399 and XPD 751 genotypes and clinical features in relation to overall survival in patients with lung cancer polymorphisms and clinicopathological factors with respect to overall survival
| Parameter | Events/censored | Median survival | Log rank P-value | Hazard ratio (95% CI) | P-value |
|---|---|---|---|---|---|
| XRCC1 399 GG | 16/47 | 31 | Reference | ||
| XRCC1 399 GA | 31/40 | 21 | 0.01 | 1.87 (0.941–3.755) | 0.07 |
| XRCC1 399 AA | 19/17 | 12 | 3.04 (1.393–6.670) | 0.005 | |
| XPD 751 AA | 29/60 | 23 | Reference | ||
| XPD751 AC | 30/40 | 20 | 0.19 | 1.34 (0.767–2.368) | 0.29 |
| XPD 751 CC | 7/4 | 14 | 2.45 (0.957–6.302) | 0.06 | |
| Stage I and II | 24/49 | 31 | 0.002 | Reference | |
| Stage III and IV | 37/37 | 14 | 2.1 (1.089–4.403) | 0.02 | |
| No metastasis | 45/86 | 31 | 1 | ||
| Metastasis | 21/18 | 15 | 0.02 | 1.08 (0.556–2.127) | 0.80 |